Baricitinib

Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, including rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. It is grouped under the following drug class(es): Immunosuppressants, JAK inhibitors, Kinase inhibitors and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as anti-inflammatories, antirheumatic agents and dermatologicals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Olumiant, baricitinibum and JAK inhibitors: baricitinib. Its PubChem CID is 44205240.